Genetic Signatures gains cash control as Microba deal advances

Restructuring halves the quarterly cash pressure

Genetic Signatures Limited (ASX:GSS) finished the first quarter of FY2027 with A$20.9 million in cash and term deposits, no debt and a substantially lower operating cash drain. Net operating cash outflow was A$1.0 million, down from A$3.4 million in the previous quarter and A$2.1 million in the prior corresponding quarter.

The improvement came as the first full quarter under the company’s restructured cost base delivered a 30% reduction in operating expenses, excluding materials, to A$4.0 million from A$5.7 million a year earlier. Staff costs fell to A$2.5 million, although the prior quarter included A$0.8 million in one-off redundancy payments, making the quarter-on-quarter comparison less clean. The earlier FY2026 cost restructure had targeted annualised savings of up to A$5 million.

Sales remain below last year despite improved receipts

Sales were A$4.0 million for the quarter, down from A$5.4 million in Q1 FY2026, while receipts from customers rose to A$4.2 million from A$3.0 million in the preceding quarter. The company said inventory levels were reduced as production was better aligned with customer demand, but cautioned that cash outflows may vary as product development costs and seasonal revenue patterns move through the business.

On the reported quarterly operating cash outflow, the Appendix 4C indicates 21.3 quarters of available funding. That is a mechanical runway calculation rather than a forecast: it assumes the quarter’s burn remains unchanged, while Genetic Signatures has explicitly warned that future outflows may fluctuate. Only A$12,000 was spent on property, plant and equipment during the quarter, and the company reported no financing facilities or borrowings.

Danish testing moves from contract to commercial use

Commercial testing began in August at Hvidovre Hospital in Denmark after installation and validation of the EasyScreen Pan-Enteric assay. The first quarter’s test supply has been delivered under the 10-year agreement, which is expected to cover 28,000 samples in its first year and grow volumes by an estimated 3% annually. The milestone converts the Danish hospital supply deal from a signed contract into an operating customer relationship, although the filing does not report revenue generated from the site in the quarter.

Microba deal adds scale but changes shareholder balance

Genetic Signatures is also pursuing an all-scrip merger with Microba Life Sciences, under which Microba shareholders would receive 0.654 new GSS shares for each Microba share and own about 67% of the combined group. The proposed Microba merger terms would bring together approximately A$29.6 million of pro forma FY2026 revenue, about A$30 million in cash and term deposits, and estimated annual gross cost synergies of A$2.5 million to A$3.0 million.

Those figures are proposed transaction benefits, not delivered results. The merger remains subject to conditions including shareholder approval, and the company’s claim that the enlarged group could reach cash-flow breakeven sooner depends on the combined operating structure and commercial execution. The all-share structure would preserve cash, but it would also leave existing GSS shareholders with a minority position in the enlarged company.

Board contest creates a near-term execution test

Shareholders are due to consider a separate governance contest at an extraordinary general meeting on 28 October. BCAL Diagnostics has requisitioned resolutions to appoint Susan Forrester and John Melki and remove Chair Michael Aicher and Dr Jenny Harry. If the resolutions pass in the combinations outlined by the company, BCAL’s nominees would hold a two-thirds majority of the reconstituted board despite BCAL holding less than 20% of GSS, while other current directors could resign immediately in specified circumstances.

The board has recommended voting against all four resolutions. That contest now sits alongside the conditional Microba transaction, APAC distribution discussions and the early commercial ramp at Hvidovre. The next phase of Genetic Signatures’ strategy therefore depends not only on whether the lower cost base holds, but on whether the company can keep its transaction and commercial agenda intact while shareholders decide who controls the board.